HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients

Creative Commons License

Files in This Item:
461576.pdf630.02 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/67551

Title: Sudden Onset of Brain Metastasis despite the Use of Vemurafenib for Another Metastatic Lesion in Malignant Melanoma Patients
Authors: Imafuku, Keisuke Browse this author
Yoshino, Koji Browse this author
Yamaguchi, Kei Browse this author
Tsuboi, Satoshi Browse this author
Ohara, Kuniaki Browse this author
Hata, Hiroo Browse this author →KAKEN DB
Keywords: Malignant melanoma
Vemurafenib
Brain metastasis
Drug resistance
BRAF mutation
Heterogeneous lesion
LDH
Issue Date: 24-Apr-2017
Publisher: Karger
Journal Title: Case reports in oncology
Volume: 10
Issue: 1
Start Page: 290
End Page: 295
Publisher DOI: 10.1159/000461576
Abstract: Vemurafenib is an inhibitor of the BRAF mutation and has been approved by the Food and Drug Administration as a treatment option for patients with unresectable melanoma without brain metastasis. In the literature, vemurafenib has been reported to be also effective against brain metastasis. We encountered 3 cases with brain metastasis on vemurafenib therapy. In these cases, vemurafenib was clinically effective against metastatic lesions other than those in the brain. The brain lesions developed after the metastatic lesion had occurred. Therefore, we assume that the melanomas of the patients acquired resistance against vemurafenib. The brain metastases were treated with the cyberknife. Patients 1 and 2 without LDH elevation are still alive, but patient 3 with abnormal LDH elevation died despite the treatment. We need to carefully follow patients on vemurafenib therapy because brain metastasis can suddenly occur even if the metastatic lesion has decreased clinically. The therapeutic effect of vemurafenib against brain metastasis is poor in cases with LDH elevation.
Rights: The final, published version of this article is available at http://www.karger.com/?doi=10.1159/000461576
https://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/67551
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 秦 洋郎

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University